In particular, these studies have demonstrated that TRF2, through its binding to the ITSs specifically located within regulatory elements (i.e. promoters and enhancers) of cancer-related genes and miRNAs [15–18], can promote an array of cellular processes – such as tumor angiogenesis and immune-escape – that participate, directly or indirectly, in the formation and the progression of the tumor. This evidence concerns the gene TERF2 and cancer.